Complete PBH Stock Valuation Analysis
Comprehensive intrinsic value analysis using 6 different methodologies
PBH DCF Analysis
PBH (Prestige Consumer Healthcare Inc.) discounted cash flow analysis with multiple scenarios, growth assumptions, and terminal value calculations
Financial Projections
| Metrics | 2023 (Historical) | 2024 (Historical) | 2025 (Historical) | 2026 (Projected) | 2027 (Projected) | 2028 (Projected) | 2029 (Projected) | 2030 (Projected) |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1B | $1.1B | $1.1B | $1.2B | $1.2B | $1.2B | $1.2B | $1.3B |
| Revenue Growth % | - | -0.2% | 1.1% | 2.7% | 2.4% | 2.1% | 1.9% | 1.7% |
| EBIT | $345.5M | $342.4M | $336.8M | $353.0M | $362.6M | $371.6M | $380.0M | $387.9M |
| EBIT Margin % | 30.6% | 30.4% | 29.6% | 30.2% | 30.3% | 30.4% | 30.5% | 30.6% |
| Tax Rate % | 25.0% | 24.2% | 24.5% | 22.9% | 23.1% | 23.4% | 23.6% | 23.8% |
| NOPAT | $259.1M | $259.7M | $254.3M | $272.0M | $278.6M | $284.8M | $290.5M | $295.7M |
| NOPAT Margin % | 23.0% | 23.1% | 22.4% | 23.3% | 23.3% | 23.3% | 23.3% | 23.3% |
| Capex | $7.8M | $9.6M | $8.2M | $12.9M | $12.5M | $12.2M | $12.5M | $12.7M |
| Capex / Revenue % | 0.7% | 0.8% | 0.7% | 1.1% | 1.0% | 1.0% | 1.0% | 1.0% |
| Depreciation | $32.6M | $30.7M | $30.2M | $32.2M | $33.0M | $33.7M | $34.3M | $34.9M |
| D&A / Revenue % | 2.9% | 2.7% | 2.7% | 2.8% | 2.8% | 2.8% | 2.8% | 2.8% |
| Change in NWC | $81.2M | $27.0M | $83.7M | $40.1M | $32.8M | $26.8M | $21.9M | $17.8M |
| NWC Change / Revenue % | 7.2% | 2.4% | 7.4% | 3.4% | 2.7% | 2.2% | 1.8% | 1.4% |
| Unlevered FCF | $202.8M | $253.9M | $192.6M | $251.3M | $266.3M | $279.5M | $290.5M | $300.2M |
| UFCF % Chg. | - | 25.2% | -24.1% | 30.5% | 6.0% | 4.9% | 4.0% | 3.3% |
| FCF / Revenue % | 18.0% | 22.6% | 16.9% | 21.5% | 22.3% | 22.9% | 23.3% | 23.7% |
| Discount Factor | - | - | - | 0.940 | 0.884 | 0.831 | 0.782 | 0.735 |
| Present Value of FCF | - | - | - | $236.2M | $235.4M | $232.3M | $227.0M | $220.6M |
| Sum of PV of UFCF | - | - | - | $236.2M | $471.7M | $703.9M | $931.0M | $1.2B |
WACC Calculation
Weighted Average Cost of Capital used for discounting cash flows.
| WACC Calculation | Value |
|---|---|
| Cost of Debt | 5.9% |
| Tax Rate | 22.9% |
| After Tax Cost of Debt | 4.5% |
| Risk Free Rate | 4.40% |
| Market Risk Premium | 4.3% |
| Beta | 0.46 |
| Cost of Equity | 6.4% |
| Total Debt | $51.9M |
| Market Cap | $4.2B |
| Total Capital | $4.2B |
| Debt Weighting | 1.2% |
| Equity Weighting | 98.8% |
| WACC | 6.4% |
Terminal Value
Choose between perpetuity growth or exit multiple methods.
| Terminal Value Calculation | Value |
|---|---|
| Terminal Growth Rate | 2.5% |
| Final Year FCF | $300.2M |
| Terminal Value | $8.0B |
| PV of Terminal Value | $5.9B |
| Cumulative PV of UFCF | $1.2B |
| Net Debt | $-46.0M |
| Equity Value | $7.1B |
| Shares Outstanding | 50.1M |
| Implied Share Price | $141 |
| Current Share Price | $85 |
| Implied Upside/(Downside) | +66.1% |
Valuation Summary
$140.97
Implied Price
$84.86
Current Price
+66.1%
Upside/Downside
6.4%
WACC
PBH Peer Valuation Analysis
Relative valuation based on comparable company trading multiples
Peer Valuation Analysis
Fair Value Range Analysis
Based on median multiples from 9 peer companies in Healthcare
P/E Ratio
$84.86
+0.0%
Peer Median: 19.8x
EV/EBITDA
$83.93
-1.1%
Peer Median: 11.7x
P/S Ratio
$35.50
-58.2%
Peer Median: 1.5x
Interpretation: Each multiple provides a different perspective on fair value. Consider which multiple is most relevant for PBH's business model and current situation.
Multiple Comparison
| Multiple | PBH Current | Peer Median | Peer Average | Premium/Discount | Assessment |
|---|---|---|---|---|---|
| P/E Ratio | 19.8x | 19.8x | 33.2x | 0.0% | Fair Value |
| EV/EBITDA | 11.7x | 11.7x | 16.6x | 0.0% | Fair Value |
| P/S Ratio | 3.7x | 1.5x | 5.2x | 139.0% | Overvalued |
Peer Companies
Click any company to view their valuation
| Company | Market Cap | P/E Ratio | EV/EBITDA | P/S Ratio |
|---|---|---|---|---|
| $10.15B | 0.0x | 14.2x | 0.7x | |
| $7.33B | 62.4x | 64.8x | 10.7x | |
| $6.83B | 18.4x | 17.1x | 1.5x | |
| $5.46B | 0.0x | 0.0x | 12.6x | |
| $4.19B | 19.8x | 11.7x | 3.7x | |
| $3.43B | 0.0x | 10.4x | 1.2x | |
| $2.49B | 3.3x | 7.1x | 0.4x | |
| $3.43B | 0.0x | 10.4x | 1.2x | |
| $728.45B | 62.3x | 45.5x | 14.9x |
PBH Graham Number
Benjamin Graham's conservative valuation formula for defensive investors
Input Data
| EPS (TTM) | $4.29 | Latest 10-K |
| Book Value per Share | $36.64 | Latest 10-K Balance Sheet |
| Graham Constant | 22.5 | Benjamin Graham's formula |
Graham Number Result
$59.44
Intrinsic Value
$84.86
Current Price
-30.0%
Upside/Downside
Confidence: High
Conservative value investing approach
Calculation Breakdown
Formula:
√(22.5 × EPS × BVPS)
Step 1: Multiply constant by EPS
22.5 × 4.29 = 96.42
Step 2: Multiply by Book Value per Share
96.42 × 36.64 = 3532.69
Step 3: Take square root
√3532.69 = 59.44
Graham Number Result:
$59.44
PBH Graham Intrinsic Value
Growth-adjusted intrinsic value with two formula variants
Formula Selection
V = EPS × (8.5 + 2g)
Graham's original P/E shortcut for growth, no interest-rate adjustment
V = [EPS × (8.5 + 2g) × 4.4] / Y
Graham's 1974 refinement: adds rate-environment sensitivity
Active Formula: Base-Growth
4.29 × (8.5 + 2 × 1.8%)
Input Data & Growth Assumptions
Current EPS (TTM)$4.29
Latest 10-K • 2025-03-31T00:00:00
Historical 3Y1.8%
Financial statements
Historical 5Y9.0%
Financial statements
Custom
%
Enter a positive growth rate estimate (0-50%)
Graham Intrinsic Value Result
$52.20
Intrinsic Value
$84.86
Current Price
-38.5%
Upside/Downside
Base Formula
Growth: 1.8%
PBH Peter Lynch Fair Value
Growth-based valuation using PEG ratio analysis for growth stocks
Fair Value Calculation
EPS (TTM)$4.29
Latest 10-K • 2025-03-31T00:00:00
Historical 3Y1.8%
3-year earnings growth
Historical 5Y9.0%
5-year earnings growth
1.8%
1%50%
Fair Value Formula: EPS × Growth Rate
$4.29 × 1.8% = $7.89
$7.89
Fair Value
$84.86
Current Price
-90.7%
Upside/Downside
PEG Analysis
19.8x
Current P/E
1.8%
Growth Rate
10.76
PEG Ratio (P/E ÷ Growth Rate)
Significantly Overvalued
PEG Ratio Interpretation:
• PEG < 1.0: Undervalued (growth exceeds P/E)
• PEG = 1.0: Fairly valued (ideal Lynch ratio)
• PEG > 1.5: Overvalued (paying premium for growth)
Peter Lynch's Rule:
"The P/E ratio of any company that's fairly priced will equal its growth rate." A stock with 15% growth should trade at a P/E of 15 (PEG = 1.0).
PBH Earnings Power Value (EPV)
Normalized earnings-based valuation for sustainable earning power assessment
Earnings Normalization
| Earnings Component | Amount ($B) | Description |
|---|---|---|
| Reported Earnings | 0.2 | Base earnings from financial statements |
| Normalized Earnings | 0.2 | Final normalized earning power |
One-time Items: Remove non-recurring gains/losses
Cyclical Adjustment: Normalize for economic cycle position
EPV Result
$47.12
EPV per Share
$84.86
Current Price
-44.5%
Upside/Downside
9.1%
WACC: 9.1% (calculated from market data)
Confidence: High
Normalized earnings approach
EPV Calculation Breakdown
Enterprise Value Calculation
| Normalized Earnings | $0.2B |
| Cost of Capital | 9.1% |
| Enterprise Value | $2.4B |
Per Share Value
| Enterprise Value | $2.4B |
| Shares Outstanding | 0.1B |
| EPV per Share | $47.12 |
WACC Components
| Cost of Equity | 9.2% |
| After-Tax Cost of Debt | 3.5% |
| Equity Weight | 98.8% |
| Debt Weight | 1.2% |
| WACC | 9.1% |